Population pharmacokinetics of artemether , lumefantrine and their 1 respective metabolites in Papua New Guinean children with uncomplicated 2 malaria
نویسندگان
چکیده
Population pharmacokinetics of artemether, lumefantrine and their 1 respective metabolites in Papua New Guinean children with uncomplicated 2 malaria 3 4 Sam Salman, Madhu Page-Sharp, Susan Griffin, Kaye Kose, Peter M. Siba, Kenneth F. 5 Ilett, Ivo Mueller, Timothy M. E. Davis 6 7 School of Medicine and Pharmacology, University of Western Australia, Fremantle 8 Hospital, Fremantle, Western Australia, Australia; School of Pharmacy, Curtin University of 9 Technology, Bentley, Australia; Papua New Guinea Institute of Medical Research, Madang, 10 Papua New Guinea 11 12 *Current addresses: Centre de Recerca en Salut Internacional de Barcelona (CRESIB), 13 Barcelona, Spain and Infection and Immunity Division, Walter and Eliza Hall Institute, 14 Parkville, Victoria, Australia. 15 16 Correspondence and reprints: Professor T. M. E. Davis, University of Western Australia, 17 School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, 18 Western Australia 6959, Australia. Telephone: +618 9431 3229; Fax: +618 9431 2977; 19 email: [email protected] 20 21 Running head: Artemether-lumefantrine pharmacokinetics in children 22 23 Copyright © 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Antimicrob. Agents Chemother. doi:10.1128/AAC.05136-11 AAC Accepts, published online ahead of print on 29 August 2011
منابع مشابه
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.
There are sparse published data relating to the pharmacokinetic properties of artemether, lumefantrine, and their active metabolites in children, especially desbutyl-lumefantrine. We studied 13 Papua New Guinean children aged 5 to 10 years with uncomplicated malaria who received the six recommended doses of artemether (1.7 mg/kg of body weight) plus lumefantrine (10 mg/kg), given with fat over ...
متن کاملArtemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial
BACKGROUND Artemisinin combination therapies (ACTs) with broad efficacy are needed where multiple Plasmodium species are transmitted, especially in children, who bear the brunt of infection in endemic areas. In Papua New Guinea (PNG), artemether-lumefantrine is the first-line treatment for uncomplicated malaria, but it has limited efficacy against P. vivax. Artemisinin-naphthoquine should have ...
متن کاملPopulation pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.
The combination of artemether (ARM) and lumefantrine is currently the first-line treatment of uncomplicated falciparum malaria in mainland Tanzania. While the exposure to lumefantrine has been associated with the probability of adequate clinical and parasitological cure, increasing exposure to artemether and the active metabolite dihydroartemisinin (DHA) has been shown to decrease the parasite ...
متن کاملPopulation Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
BACKGROUND The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. METHODS Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan children, ages 6 months to 2 years, who were treated for 249 episodes of ...
متن کاملArtemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria
Artemether-lumefantrine is a first-line regimen for the treatment of uncomplicated malaria during the second and third trimesters of pregnancy. Previous studies have reported changes in the pharmacokinetics and clinical outcomes following treatment with artemether-lumefantrine in pregnant women compared to nonpregnant adults; however, the results are inconclusive. We conducted a study in rural ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2011